Terutroban
产品说明书
 |
同义名 : | S-18886; Triplion |
| CAS号 : | 165538-40-9 | |
| 货号 : | A287410 | |
| 分子式 : | C20H22ClNO4S | |
| 纯度 : | 98%+ | |
| 分子量 : | 407.91 | |
| MDL号 : | MFCD28411833 | |
| 存储条件： |
Pure form Sealed in dry, store in freezer, under -20°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | TP (thromboxane-A2 /prostaglandin-endoperoxide)-receptor blockade with terutroban decreases portal pressure in cirrhosis[3]. Terutroban is a selective TP receptor antagonist, i.e. a specific antagonist of the thromboxane A(2) and prostaglandin endoperoxide receptors, shown to improve endothelial function after a single administration in patients with coronary artery disease. It can chronically improve endothelium-dependent vasodilatation and inhibiting platelet aggregation[4]. Terutroban prevents the development of aorta hyperplasia and has beneficial effects on fibrotic processes by affecting TGF-β and heat shock protein-47 expression in SHRSPs(spontaneously hypertensive stroke-prone rats)[5]. Terutroban significantly protected retinal vascularity from ischaemia in experimental diabetes, and this result could be attributed not only to its antiplatelet/antithrombotic activities but also to its vascular properties[6]. In PAD (peripheral arterial disease) patients, terutroban dose-dependently inhibited platelet aggregation 24 h after dosing, and was at least as effective as aspirin at 5, 10 and 30 mg day(-1). Terutroban was well tolerated[7]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.45mL 0.49mL 0.25mL |
12.26mL 2.45mL 1.23mL |
24.52mL 4.90mL 2.45mL |
| 参考文献 |
|---|